Why the study?
Does bevacizumab increase the risk of hypertension in patients with non-small-cell lung cancer?
Population
3,155 patients with non-small-cell lung cancer (NSCLC) pooled from 9 randomized controlled trials
Comparison
Bevacizumab vs Control group (specifics not detailed in abstract)
Design
Meta-analysis
Authors
Loading...
Bevacizumab raises hypertension risk in NSCLC; leaves open need for standardized monitoring and dose-specific trials.
Does bevacizumab increase the risk of hypertension in patients with non-small-cell lung cancer?
Bevacizumab therapy in non-small-cell lung cancer patients is associated with a markedly increased risk of developing hypertension, necessitating early monitoring and management.
Zheng et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: